EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research

E Dawn Flick, Howard R Terebelo, Susan Fish, Amani Kitali, Vrinda Mahajan, Melissa Nifenecker, Kristen Sullivan, Paul Thaler, Sarah Ussery, David L Grinblatt

The Oncologist · 03.08.2023 · 28 (8) · 657-663

DOI: 10.1093/oncolo/oyad110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 07.06.2023. Verfasst von E Dawn Flick und 9 weiteren Autor:innen. Beteiligte Einrichtung: Worldwide Health Economics and Outcomes Research (HEOR), Bristol Myers Squibb, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Drug Industry. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In May 2019, the US Food and Drug Administration (FDA) released the Framework for FDA’s Real-World Evidence (RWE) Program, a draft guidance to evaluate the potential use of real-world data in facilitating regulatory decisions. As a result, pharmaceutical companies and medical communities see patient registries, which are large, prospective, noninterventional cohort studies, as becoming increasingly important in providing evidence of treatment effectiveness and safety in clinical practice. Patient registries are designed to collect longitudinal clinical data on a broad population to address critical medical questions over time. With their large sample sizes and broad inclusion criteria, patient registries are often used to generate RWE in the general and underrepresented patient populations that are less likely to be studied in controlled clinical trials. Here, we describe the value of industry-sponsored patient registries in oncology/hematology settings to healthcare stakeholders, in drug development, and in fostering scientific collaboration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryHumansProspective StudiesTreatment OutcomeRegistries

Stichwörter der Autor:innen

observational studyoncologyprospective cohort studyreal-world evidenceregistry

Autor:innen und Institutionen

  • Worldwide Health Economics and Outcomes Research (HEOR), Bristol Myers Squibb, San Francisco, CA, USA.
  • Providence Cancer Institute, Southfield, MI, USA.
  • US Medical Affairs, Bristol Myers Squibb, Summit, NJ, USA.
  • Corporate Medical Affairs, Global Scientific Communications, Bristol Myers Squibb, Summit, NJ, USA.
  • Research and Early Development Alliances, Bristol Myers Squibb, Summit, NJ, USA.
  • NorthShore University HealthSystem, Evanston, IL, USA.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Flick, E. D., Terebelo, H. R., Fish, S., Kitali, A., Mahajan, V., Nifenecker, M., Sullivan, K., Thaler, P., Ussery, S., & Grinblatt, D. L. (2023). The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research. The Oncologist, 28(8), 657-663. https://doi.org/10.1093/oncolo/oyad110

Vancouver

Flick ED, Terebelo HR, Fish S, Kitali A, Mahajan V, Nifenecker M, et al. The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research. The Oncologist. 2023;28(8):657-663. doi:10.1093/oncolo/oyad110

BibTeX
@article{Flick2023,
  author = {Flick, E Dawn and Terebelo, Howard R and Fish, Susan and Kitali, Amani and Mahajan, Vrinda and Nifenecker, Melissa and Sullivan, Kristen and Thaler, Paul and Ussery, Sarah and Grinblatt, David L},
  title = {The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {8},
  pages = {657--663},
  doi = {10.1093/oncolo/oyad110}
}
Kostenlos starten →